MYGN

Companies
NASDAQ
Myriad Genetics Inc.
Health Care
Price Chart
Overview

About MYGN

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

Market Cap
$2.0B
Volume
4.2M
Avg. Volume
5.5M
P/E Ratio
54
Dividend Yield
271.67%
Employees
2.7K

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Diagnostics & Research
Risk & Correlation Analysis
Market Correlation
1.49
High Correlation
Volatility
High (0.54)
Relative to market

Macro Factor Sensitivities

Interest Rates
Medium Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for MYGN.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, MYGN shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$2.0B
Volume4.2M
P/E Ratio54.00
Dividend Yield271.67%
Important Dates
Next Dividend
Next Earnings
November 8, 2024

PortfolioPilot Analysis

Get AI-powered insights on how MYGN fits into your investment strategy and portfolio diversification.

Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025